本文選題：PRCA + 胸腺瘤��； 參考：《中國現(xiàn)代醫(yī)學(xué)雜志》2017年07期

【摘要】：目的調(diào)查我國單純紅細(xì)胞再生障礙性貧血(PRCA)合并胸腺瘤(Ts)伴重癥肌無力(MG)病例特點,反應(yīng)現(xiàn)存臨床處理風(fēng)險,積累診治經(jīng)驗,為其臨床處理提供參考。方法回顧2011年該院收治的1例PRCA合并Ts伴MG病例資料,結(jié)合2000~2016年應(yīng)用相關(guān)期刊論文、維普數(shù)據(jù)庫、萬方數(shù)據(jù)庫及PubMed檢索系統(tǒng),檢索出PRCA合并Ts相關(guān)國內(nèi)文獻(xiàn)32篇(共82例,包括本院1例)、國外文獻(xiàn)29篇(共62例)的臨床資料,主要分析中國目前PRCA合并Ts伴MG不同治療方法與預(yù)后的影響。結(jié)果納入調(diào)查的外國62例患者中,在2004年時逐步使用術(shù)后放射治療(PORT)技術(shù)。國內(nèi)82例患者中,PORT技術(shù)的應(yīng)用在2008年的文獻(xiàn)中開始體現(xiàn),≤2008年的文獻(xiàn)顯示僅有3例患者應(yīng)用PORT技術(shù),還存在一些因經(jīng)濟(jì)原因放棄PORT的患者。使治療方法與預(yù)后的結(jié)果無統(tǒng)計學(xué)意義(P=0.064)。結(jié)論手術(shù)是首選治療方法,行PORT前必須明確患者M(jìn)G癥狀是否改善或治愈,否則在PORT治療中會出現(xiàn)肌無力危象。目前并無標(biāo)準(zhǔn)治療方案,建議根據(jù)手術(shù)方式和組織學(xué)分擇優(yōu)選擇方案。建立規(guī)范化的管理流程是降低腫瘤復(fù)發(fā)率和提高患者生存率的關(guān)鍵。
[Abstract]:Objective to investigate the characteristics of simple erythrocyte aplastic anemia (PRCA) combined with thymoma (Ts) with myasthenia gravis (MG), to respond to the existing risk of clinical management, to accumulate experience in diagnosis and treatment, and to provide reference for clinical management. Methods A case of PRCA with ts with MG was retrospectively reviewed in 2011, and the Chinese Journal Full-text Database, Weip Database, Wanfang Database and PubMed Retrieval system were used in 2000 ~ 2016. The clinical data of 32 articles (82 cases) related to PRCA and ts were retrieved, including 1 case in our hospital and 29 cases (62 cases in foreign literature). The effects of different treatment methods and prognosis of PRCA combined with ts with MG in China were analyzed. Results among the 62 foreign patients surveyed, post-operative radiotherapy (PORT) technique was used step by step in 2004. The application of polt technique in 82 patients in China began to manifest in the literature of 2008. The literature of 鈮，

本文編號：2030014